| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20038030 | HPV | ENSG00000133019.12 | protein_coding | CHRM3 | No | No | 1131 | P20309 |
| TVIS20048589 | HPV | ENSG00000133019.12 | protein_coding | CHRM3 | No | No | 1131 | P20309 |
| TVIS20026706 | HPV | ENSG00000133019.12 | protein_coding | CHRM3 | No | No | 1131 | P20309 |
| TVIS20048288 | HPV | ENSG00000133019.12 | protein_coding | CHRM3 | No | No | 1131 | P20309 |
| TVIS20033039 | HPV | ENSG00000133019.12 | protein_coding | CHRM3 | No | No | 1131 | P20309 |
| TVIS20021233 | HPV | ENSG00000133019.12 | protein_coding | CHRM3 | No | No | 1131 | P20309 |
| TVIS20032030 | HPV | ENSG00000133019.12 | protein_coding | CHRM3 | No | No | 1131 | P20309 |
| TVIS44018639 | HTLV-1 | ENSG00000133019.12 | protein_coding | CHRM3 | No | No | 1131 | P20309 |
| TVIS44021744 | HTLV-1 | ENSG00000133019.12 | protein_coding | CHRM3 | No | No | 1131 | P20309 |
| TVIS44029331 | HTLV-1 | ENSG00000133019.12 | protein_coding | CHRM3 | No | No | 1131 | P20309 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CHRM3 |
|---|---|
| DrugBank ID | DB01062 |
| Drug Name | Oxybutynin |
| Target ID | BE0000045 |
| UniProt ID | P20309 |
| Regulation Type | antagonist |
| PubMed IDs | 19275276; 19446545; 20590605; 17222678; 16406943; 7620236 |
| Citations | Baldwin CM, Keating GM: Transdermal oxybutynin. Drugs. 2009;69(3):327-37. doi: 10.2165/00003495-200969030-00008.@@Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S: Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. Epub 2009 May 13.@@Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x.@@Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70.@@Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, Yamada S: Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol. 2006 Jan;175(1):365-9.@@Yarker YE, Goa KL, Fitton A: Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging. 1995 Mar;6(3):243-62. doi: 10.2165/00002512-199506030-00007. |
| Groups | Approved; Investigational |
| Direct Classification | Benzene and substituted derivatives |
| SMILES | CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1 |
| Pathways | |
| PharmGKB | PA164746030 |
| ChEMBL | CHEMBL1231 |
